These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35381199)

  • 1. LGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma.
    Gur C; Wang SY; Sheban F; Zada M; Li B; Kharouf F; Peleg H; Aamar S; Yalin A; Kirschenbaum D; Braun-Moscovici Y; Jaitin DA; Meir-Salame T; Hagai E; Kragesteen BK; Avni B; Grisariu S; Bornstein C; Shlomi-Loubaton S; David E; Shreberk-Hassidim R; Molho-Pessach V; Amar D; Tzur T; Kuint R; Gross M; Barboy O; Moshe A; Fellus-Alyagor L; Hirsch D; Addadi Y; Erenfeld S; Biton M; Tzemach T; Elazary A; Naparstek Y; Tzemach R; Weiner A; Giladi A; Balbir-Gurman A; Amit I
    Cell; 2022 Apr; 185(8):1373-1388.e20. PubMed ID: 35381199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of RXFP1 in skin of scleroderma patients and control subjects.
    Giordano N; Volpi N; Franci D; Corallo C; Fioravanti A; Papakostas P; Montella A; Biagioli M; Fimiani M; Grasso G; Muscettola MM; Guerranti R; Vannoni D; Galeazzi M; Nuti R
    Scand J Rheumatol; 2012 Oct; 41(5):391-5. PubMed ID: 23043266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.
    Affandi AJ; Carvalheiro T; Ottria A; Broen JC; Bossini-Castillo L; Tieland RG; Bon LV; Chouri E; Rossato M; Mertens JS; Garcia S; Pandit A; de Kroon LM; Christmann RB; Martin J; van Roon JA; Radstake TR; Marut W
    Ann Rheum Dis; 2019 Sep; 78(9):1249-1259. PubMed ID: 31126957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myofibroblast transcriptome indicates SFRP2
    Tabib T; Huang M; Morse N; Papazoglou A; Behera R; Jia M; Bulik M; Monier DE; Benos PV; Chen W; Domsic R; Lafyatis R
    Nat Commun; 2021 Jul; 12(1):4384. PubMed ID: 34282151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time.
    Skaug B; Lyons MA; Swindell WR; Salazar GA; Wu M; Tran TM; Charles J; Vershel CP; Mayes MD; Assassi S
    Ann Rheum Dis; 2022 Apr; 81(4):516-523. PubMed ID: 34937693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis.
    Usategui A; Criado G; Izquierdo E; Del Rey MJ; Carreira PE; Ortiz P; Leonard WJ; Pablos JL
    Ann Rheum Dis; 2013 Dec; 72(12):2018-23. PubMed ID: 23413283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [THE ROLE OF SEMAPHORIN 7A IN SYSTEMIC SCLEROSIS].
    Rimar D; Slobodin G; Rosner I; Rozenbaum M; Kaly L; Boulman N; Jiries N; Awisat A; Vadasz Z
    Harefuah; 2017 Jul; 156(7):418-421. PubMed ID: 28786275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic sclerosis (scleroderma): specific autoantigen genes are selectively overexpressed in scleroderma fibroblasts.
    Zhou X; Tan FK; Xiong M; Milewicz DM; Feghali CA; Fritzler MJ; Reveille JD; Arnett FC
    J Immunol; 2001 Dec; 167(12):7126-33. PubMed ID: 11739535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
    Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
    Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis.
    Kondo M; Suzuki T; Kawano Y; Kojima S; Miyashiro M; Matsumoto A; Kania G; Błyszczuk P; Ross RL; Mulipa P; Del Galdo F; Zhang Y; Distler JHW
    Arthritis Res Ther; 2022 Sep; 24(1):210. PubMed ID: 36050717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The membrane-associated adaptor protein DOK5 is upregulated in systemic sclerosis and associated with IGFBP-5-induced fibrosis.
    Yasuoka H; Yamaguchi Y; Feghali-Bostwick CA
    PLoS One; 2014; 9(2):e87754. PubMed ID: 24551065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profibrotic Activation of Human Macrophages in Systemic Sclerosis.
    Bhandari R; Ball MS; Martyanov V; Popovich D; Schaafsma E; Han S; ElTanbouly M; Orzechowski NM; Carns M; Arroyo E; Aren K; Hinchcliff M; Whitfield ML; Pioli PA
    Arthritis Rheumatol; 2020 Jul; 72(7):1160-1169. PubMed ID: 32134204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta.
    McCoy SS; Reed TJ; Berthier CC; Tsou PS; Liu J; Gudjonsson JE; Khanna D; Kahlenberg JM
    Rheumatology (Oxford); 2017 Nov; 56(11):1970-1981. PubMed ID: 28968684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis.
    MacDonald KG; Dawson NAJ; Huang Q; Dunne JV; Levings MK; Broady R
    J Allergy Clin Immunol; 2015 Apr; 135(4):946-955.e9. PubMed ID: 25678090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the pro-fibrotic phenotype of fibroblasts in systemic sclerosis.
    Maier C; Distler JH; Beyer C
    Exp Dermatol; 2014 Feb; 23(2):99-100. PubMed ID: 24476007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan and its metabolite SN38 inhibits procollagen I production of dermal fibroblasts from Systemic Sclerosis patients.
    Lapoirie J; Tran L; Piazza L; Contin-Bordes C; Truchetet ME; Bonnet F
    Sci Rep; 2021 Sep; 11(1):18011. PubMed ID: 34504265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of the transforming growth factor β-inducible gene HIC-5 in systemic sclerosis skin and fibroblasts: a novel antifibrotic therapeutic target.
    Piera-Velazquez S; Fertala J; Huaman-Vargas G; Louneva N; Jiménez SA
    Rheumatology (Oxford); 2020 Oct; 59(10):3092-3098. PubMed ID: 32442272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
    Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
    Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.